Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study

哌醋甲酯 耐受性 注意缺陷多动障碍 精神科 医学 儿科 心理健康 阿托莫西汀 不利影响 心理学 临床心理学 内科学
作者
Kenneth K. C. Man,Alexander Häge,Tobias Banaschewski,Sarah Karen Inglis,Jan K. Buitelaar,Sara Carucci,Marina Danckaerts,Regina Dittmann,Bruno Falissard,Peter Garas,Chris P. Hollis,Kerstin Konrad,Hanna Kovshoff,Elizabeth B. Liddle,Suzanne McCarthy,Antje C. Neubert,Péter Nagy,Éric Rosenthal,Edmund J. S. Sonuga-Barke,Alessandro Zuddas
出处
期刊:The Lancet Psychiatry [Elsevier BV]
卷期号:10 (5): 323-333 被引量:99
标识
DOI:10.1016/s2215-0366(23)00042-1
摘要

BACKGROUND: Methylphenidate is the most frequently prescribed medication for the treatment of ADHD in children and adolescents in many countries. Although many randomised controlled trials support short-term efficacy, tolerability, and safety, data on long-term safety and tolerability are scarce. The aim of this study was to investigate the safety of methylphenidate over a 2-year period in relation to growth and development, psychiatric health, neurological health, and cardiovascular function in children and adolescents. METHODS: We conducted a naturalistic, longitudinal, controlled study as part of the ADDUCE research programme in 27 European child and adolescent mental health centres in the UK, Germany, Switzerland, Italy, and Hungary. Participants aged 6-17 years were recruited into three cohorts: medication-naive ADHD patients who intended to start methylphenidate treatment (methylphenidate group), medication-naive ADHD patients who did not intend to start any ADHD medication (no-methylphenidate group), and a control group without ADHD. Children with ADHD diagnosed by a qualified clinician according to the DSM-IV criteria and, in the control group, children who scored less than 1·5 on average on the Swanson, Nolan, and Pelham IV rating scale for ADHD items, and whose hyperactivity score on the parent-rated Strengths and Difficulties Questionnaire was within the normal range (<6) were eligible for inclusion. Participants were excluded if they had previously taken any ADHD medications but remained eligible if they had previously taken or were currently taking other psychotropic drugs. The primary outcome was height velocity (height velocity SD score; estimated from at least two consecutive height measurements, and normalised with reference to the mean and SD of a population of the same age and sex). FINDINGS: Between Feb 01, 2012, and Jan 31, 2016, 1410 participants were enrolled (756 in methylphenidate group, 391 in no-methylphenidate group, and 263 in control group). 1070 (76·3%) participants were male, 332 (23·7%) were female, and for eight gender was unknown. The average age for the cohort was 9·28 years (SD 2·78; IQR 7-11). 1312 (93·0%) of 1410 participants were White. The methylphenidate and no-methylphenidate groups differed in ADHD symptom severity and other characteristics. After controlling for the effects of these variables using propensity scores, there was little evidence of an effect on growth (24 months height velocity SD score difference -0·07 (95% CI -0·18 to 0·04; p=0·20) or increased risk of psychiatric or neurological adverse events in the methylphenidate group compared with the no-methylphenidate group. Pulse rate and systolic and diastolic blood pressure were higher in the methylphenidate group compared with the no-methylphenidate group after 24 months of treatment. No serious adverse events were reported during the study. INTERPRETATION: Our results suggest that long-term treatment with methylphenidate for 2 years is safe. There was no evidence to support the hypothesis that methylphenidate treatment leads to reductions in growth. Methylphenidate-related pulse and blood pressure changes, although relatively small, require regular monitoring. FUNDING: EU Seventh Framework Programme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
orange发布了新的文献求助10
刚刚
fight完成签到,获得积分10
刚刚
小小发布了新的文献求助50
刚刚
深情雨泽发布了新的文献求助10
刚刚
青年晚报完成签到,获得积分10
1秒前
灵巧雪枫完成签到,获得积分10
1秒前
1秒前
fsy完成签到 ,获得积分10
1秒前
兴奋冰绿完成签到 ,获得积分10
2秒前
陈熙完成签到 ,获得积分10
3秒前
Ww完成签到,获得积分10
4秒前
化学完成签到 ,获得积分10
4秒前
gatto完成签到,获得积分10
4秒前
youctunxi完成签到,获得积分10
4秒前
HHH完成签到,获得积分10
4秒前
乐乐的应助被fhn716采纳,获得10
4秒前
4秒前
梧桐完成签到,获得积分10
5秒前
隐形曼青的应助被fhn716采纳,获得10
5秒前
lan发布了新的文献求助10
5秒前
追寻的问玉完成签到 ,获得积分10
5秒前
月上卿云发布了新的文献求助10
6秒前
开放舞蹈完成签到,获得积分10
6秒前
6秒前
哈哈哈完成签到,获得积分10
6秒前
傅礼貌完成签到,获得积分10
6秒前
瑟瑟考拉完成签到 ,获得积分10
6秒前
7秒前
luotao完成签到,获得积分10
7秒前
青鱼完成签到,获得积分10
7秒前
传奇3的应助被高山我梦采纳,获得10
7秒前
孙悟空完成签到,获得积分10
8秒前
小半完成签到 ,获得积分10
8秒前
顾矜的应助被Caicai采纳,获得10
8秒前
8秒前
科研CY完成签到 ,获得积分10
9秒前
yunwen完成签到,获得积分10
9秒前
肖未央完成签到,获得积分10
9秒前
外向的雁玉完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180189
求助须知:如何正确求助?哪些是违规求助? 9570320
关于积分的说明 21810161
捐赠科研通 7776320
什么是DOI,文献DOI怎么找? 3433267
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039